Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Jubilant Life signs...

    Jubilant Life signs $180 mn outlicensing deal with Checkpoint

    Written by savita thakur thakur Published On 2016-05-29T18:17:37+05:30  |  Updated On 29 May 2016 6:17 PM IST

    NEW DELHI: Drug firm Jubilant Life Sciences (JLS) announced a $180 million out-licensing pact with Checkpoint Therapeutics Inc for a family of patented compounds to be developed for cancer treatment.


    The company's subsidiary Jubilant Biosys and Checkpoint Therapeutics Inc have signed an exclusive, worldwide license deal, under which Checkpoint will assume all its further pre-clinical, clinical development and commercialisation responsibilities, JLS said in a BSE filing.

    The pact includes an upfront payment of $2 million and contingent pre-clinical, clinical and regulatory payments including commercial milestones totaling up to $180 million, it added.

    As per the agreement, "Jubilant Biosys will out-license to Checkpoint a family of patents covering compounds that inhibit BRD4, a member of the BET domain for cancer treatment."

    Jubilant Biosys will also receive research funding and royalty payments on successful commercialisation of the compounds, it added.

    JLS Chairman Shyam S Bhartia and Co-Chairman and MD Hari S Bhartia said, "This agreement represents our first out-licensing deal which is a testament to our investment in innovation in the pharmaceutical business."

    Jubilant had decided to make strategic investments in proprietary drug discovery of small molecules with an intent to out-license the same for upfront payments and phased milestone payments/royalties, they added.

    "This agreement enhances our current product portfolio of immuno-oncology and targeted anti-cancer agents," Checkpoint President and CEO James F Oliviero III said.

    BET inhibitors have generated significant excitement within the oncology community and "Jubilant's asset provides us with additional opportunities to explore proprietary combinations and treatment options for patients," he added.
    Jubilant Biosys LtdJubilant Life SciencesTherapeutics Inc
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok